Market Assessment, Otezla Psoriatic Arthritis Wave 1 LaunchTrends US 2014 Report

This LaunchTrends report series will track the post-launch awareness, trial, and usage of Apremilast (Otezla) among rheumatologists for the treatment of Psoriatic Arthritis. Three waves of the syndicated report will assess physician perceptions at one month, six months and one year after the launch of Apremilast. The reports will further explore where Apremilast is being placed in the treatment algorithm and in which patient types, strengths and weaknesses of the product profile compared to other agents, and the overall impact of the launch on the market landscape.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Otezla (Psoriatic Arthritis) (Wave 1) | LaunchTrends | US | 2014

Related Market Assessment Reports

Asthma | Unmet Need | Severe Asthma | US/EU | 2021

Pulmonary Hypertension – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Asthma – Unmet Need – Detailed, Expanded Analysis – Severe Asthma (US/EU)

Crohn’s Disease – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Pediatric Crohn’s Disease (US)

Chronic Kidney Disease – Current Treatment – Detailed, Expanded Analysis – Treatment Algorithms – Claims Data Analysis (US)